<DOC>
	<DOCNO>NCT00871910</DOCNO>
	<brief_summary>Part 1 Part 2 trial evaluate safety , tolerability , maximum administer dose , dose limit toxicity SCH 727965 administer every 3 week 2 hour intravenous ( IV ) infusion ( Part 1 ) , 8-hour 24-hour IV infusion ( Part 2 ) . Each 3-week period consider one treatment cycle . Part 3 trial evaluate effect coadministration antiemetic drug aprepitant pharmacokinetics SCH 727965 administer 2 hour IV infusion every 3 week .</brief_summary>
	<brief_title>Phase 1 Every-3-Week Dosing SCH 727965 Patients With Advanced Cancer ( Study P04630 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt; =18 year , either sex , race . Subjects must histologically prove solid tumor , nonHodgkin 's lymphoma , multiple myeloma . There must know standard therapy , disease must refractory standard therapy . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 . Adequate hematologic , renal , hepatic organ function laboratory parameter . Symptomatic brain metastasis primary central nervous system malignancy . Previous radiation therapy &gt; 25 % total bone marrow . Previous treatment SCH 727965 . Known HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>